OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0334

Negative Pressure Wound Therapy

Customize your policy alerts

Sign up for Aetna Policy 0334 alerts

Get alerted when Policy 0334 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity, contraindications, continuation and discontinuation criteria, supply limits, and coding for negative pressure wound therapy for Aetna members in covered settings.

Policy Summary

PayerAetna

PolicyNegative Pressure Wound Therapy

Policy CodePolicy 0334

Change TypeNo material change

Effective DateAug 16, 1999

Last ReviewDec 13, 2023

Next Review DateMar 28, 2024

Key ActionObtain prior authorization when billing NPWT pumps and supplies and document wound type, measurements, debridement, and monthly progress to support continued coverage.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

30 daysminimum chronic ulcer duration for home NPWT eligibility

4 monthsmaximum routine NPWT duration before individual consideration

15maximum dressing kits per wound per month

10maximum canister sets per month

9NNT to prevent 1 SSI after ventral hernia repair (meta-analysis)

95%+wound graft take (large burns/STSG)

Coverage Criteria for NPWT

Continuation Therapy

Continued medical necessity while on NPWT

Continued Medical Necessity: Licensed medical professional must regularly assess the wound(s) and supervise or directly perform NPWT dressing changes AND document changes in the ulcer's dimensions and characteristics at least monthlymonthly

Once-weekly NPWT is considered medically necessary; supplier should obtain monthly clinician assessment to justify continued equipment and supplies

Discontinuation Criteria

Discontinuation — NPWT considered not medically necessary if ANY of the following occur

Discontinuation Criteria: 1) Any measurable degree of wound healing has failed to occur over the prior month (no improvement in surface area or depth with documentation) OR 2) Four months have elapsed using NPWT for the wound (including inpatient time) unless individual consideration with additional documentation is provided OR 3) In the treating physician's judgment adequate wound healing has occurred to discontinue NPWT OR 4) Equipment or supplies are no longer being used for the member OR 5) Continued medical necessity criteria (regular assessments and monthly documented measurements) are no longer met

Policy Summary

PayerAetna

PolicyNegative Pressure Wound Therapy

Policy CodePolicy 0334

Change TypeNo material change

Effective DateAug 16, 1999

Last ReviewDec 13, 2023

Next Review DateMar 28, 2024

Key ActionObtain prior authorization when billing NPWT pumps and supplies and document wound type, measurements, debridement, and monthly progress to support continued coverage.

SourceLink

On This Page

Quantitative wound measurements must be documented serially and compared month-to-month

Experimental/Investigational / Not Covered Uses

Experimental, investigational, and not covered indications

Experimental/Investigational/Not Covered: Includes continuous- or intermittent-instillation of chemotherapeutic agents (eg, doxycycline, insulin) in NPWT; non-powered mechanical NPWT devices (eg, SNaP) for indicated uses; single-use NPWT devices (eg, PICO, Prevena) for all indications in this policy; VeraFlo (intermittent-instillation) for wound healing including diabetic foot ulcer; Wound Vac for full-thickness burns; and multiple listed prophylactic or unestablished indications (eg, routine prophylactic use after cesarean delivery, ventral hernia repair, pancreatectomy, certain cardiac/knee arthroplasty or reconstruction indications, fracture-related infections, open fracture/traumatic wounds) as specified in the policy

List is not exhaustive; single-use devices may also be excluded under plans that exclude supplies

Evidence-based coverage considerations

Evidence summary & contextual considerations from the policy document

Evidence base summary: Multiple systematic reviews, technology assessments, and RCTs have produced mixed-quality evidence for NPWT across wound types; some trials (eg, Blume 2008 for DFU) show benefit while many reviews cite insufficient high-quality evidence and call for larger, standardized RCTs

See AHRQ, Cochrane and multiple systematic reviews cited

Device considerations: Single-use and non-powered devices exist; comparative trials (eg, SNaP versus VAC) show noninferiority in select noninfected diabetic/venous wounds but generalizability is limited and device-specific superiority is not established

Armstrong 2012 and related device reports cited

Specific wound contexts: NPWT has been studied in chronic wounds, pressure ulcers, diabetic foot ulcers, open abdomen, skin grafts, burns, closed incisions and trauma; evidence strength varies by indication with some supportive data (eg, STSG bolster, certain ciNPWT uses) and important evidence gaps in many areas

NICE supports open abdomen use with governance; Cochrane reviews found insufficient evidence for partial-thickness burns

Coverage considerations and conditional evidence

Coverage stance and conditional considerations summarized from the evidence:

Incisional/prophylactic NPWT evidence: RCTs and observational studies suggest potential reductions in surgical-site complications for selected surgeries (eg, ventral hernia, groin incisions, some orthopedic settings), but overall evidence is mixed and of variable quality; systematic reviews find uncertain efficacy for many prophylactic incisional uses

See Cochrane and systematic review findings

Cost-effectiveness considerations for prophylactic NPWT: Prophylactic NPWT may be cost-beneficial primarily in high-risk populations or when device price is below a threshold; standard dressing is preferred for low-risk patientsSSI rate >14% or device price < $192

Based on decision-analytic modeling (Echebiri et al)

Specialty indications with supportive data: Supportive but limited evidence exists for select indications (eg, improved graft take in burns/STSG, reduced SSI in some groin/vascular and revision arthroplasty settings, benefit of NPWTi in infected wounds), but further high-quality trials are needed

See cited specialty reviews and trials

Indication-specific evidence summaries

Coverage and medical necessity depend on clinical indication and supporting evidence; summarized findings from the document:

Burns: NPWT as a bolster for skin autografts improves graft take in multiple studies and may be considered when securing STSGs or managing large/full-thickness burns

Kantak review and Kamolz large-burn series cited

Closed incisional management after cardiac/sternotomy settings: Preliminary cohort and prospective data suggest potential reductions in deep sternal wound infection with NPWT, but definitive RCT evidence is limited

Small cohort studies referenced

Knee arthroplasty: Small RCTs show mixed results for NPWT after knee arthroplasty with modest QoL advantages but no clear wound-healing benefit

Manoharan and related trials

Open resection of intra-abdominal malignancy: Randomized trial found no reduction in incisional SSI with NPWT versus standard dressing; NPWT not supported to decrease SSI in this population based on current trial evidence

Shen RCT

Prophylactic iNPWT after cesarean delivery: Meta-analyses in primarily obese/high-risk women report reduced SSI and composite wound complications; cost-effectiveness analyses suggest potential value in higher-BMI subgroups (eg, >=35 kg/m2)BMI >= 30 kg/m2 inclusion; subgroup benefit >=35 kg/m2

Yu meta-analysis and Hyldig cost-effectiveness

Fasciotomy wounds/compartment syndrome: Systematic reviews and AAOS guidance support use of NPWT to improve primary closure rates and reduce complications among closure techniques

Jauregui and Cone/Inaba analyses

Indication-specific evidence summaries

Evidence and coverage considerations vary by indication — examples below reflect published trial and review findings.

Prophylactic/incisional NPWT after cesarean delivery: RCTs and meta-analyses suggest reduced SSI and wound complications in obese/high-risk women, with cost-effectiveness more favorable in higher BMI subgroups; larger definitive trials are still neededBMI thresholds noted in trials (>=30 kg/m2; subgroup >=35 kg/m2)

Yu meta-analysis; Hyldig cost-effectiveness

Closed groin incisions (arterial/vascular surgery): Meta-analyses of RCTs (eg, 7 RCTs, ~1,049 incisions) show reduced SSI with ciNPWT (OR ~0.35); evidence graded moderate but further high-quality RCTs with cost analyses advisednone

Svensson-Bjork review

Open fractures/traumatic wounds: Cochrane and systematic reviews report uncertain benefit for NPWT at 125 mmHg on wound healing and infection; moderate- to low-certainty evidence and potential lack of cost-effectiveness in some settings

Iheozor-Ejiofor and Webster reviews

Head and neck wounds with fistulas: Case series report high closure rates with NPWT but evidence is low quality and heterogeneous, precluding definitive recommendations

Level IV studies only

Pilonidal disease: Limited case series and retrospective data suggest potential emerging use for complex/recurrent disease, but randomized data are lacking and NPWT remains investigational for this indication

Further trials needed

Coverage considerations and device-selection guidance

Clinical and evidence-based considerations for use of NPWT and s-NPWT:

s-NPWT recommended considerations: When NPWT is appropriate, single-use NPWT (s-NPWT) may be preferred for ambulatory patients, prophylactic use on closed incisions in patients with risk factors, and wounds eligible by size/type where portability and patient quality of life matter

Consensus statements and meta-analyses support s-NPWT benefits in risk-factor populations

t-NPWT appropriate situations: Traditional (canister-based) NPWT is appropriate for large, complex wounds requiring inpatient stabilization, higher negative pressures, or long-term therapy; transition to s-NPWT may be considered for outpatient management when clinically appropriate

Consensus and trial rationale

Evidence for s-NPWT efficacy: RCTs demonstrate noninferiority or superior wound-area/volume reduction and higher closure rates for s-NPWT versus t-NPWT in select VLU/DFU trials, with economic models indicating potential cost savings

Kirsner RCT and cost-effectiveness modeling cited

Coverage considerations by indication

Coverage considerations based on available evidence summaries in the document.

Burns and large STSG fixation: NPWT used as a bolster for split-thickness skin grafts in large burns and hard-to-fix sites has been associated with high graft take rates (>95% in some series) and may be considered medically necessary when used to secure STSGs or manage large/full-thickness burns

Kamolz and STSG systematic reviews/meta-analyses support graft-take benefits

STSG fixation generally: Meta-analyses and cohort studies show higher graft take and reduced re-operation with NPWT versus conventional therapy; consider covered when clinically indicated to improve graft adherence

Yin meta-analysis; Li, Mo cohort studies

ciNPWT after arthroplasty and spinal fusion: ciNPWT reduced wound complications and SSI in high-risk and revision THA/TKA and after spinal fusion in randomized and meta-analytic data; consider covered for high-risk or revision arthroplasty and selected spinal fusion cases but not routinely for all primary arthroplasty due to variable benefit and increased non-infectious complications (eg, blistering) in some primary TKA studieshigh-risk or revision procedures

Ailaney, Kim & Lee, Lambrechts analyses

Fracture-related infections (FRI): Evidence is low-quality and heterogeneous; NPWT is not clearly recommended as definitive therapy for FRI and may be used only temporarily until definitive soft tissue coverage is performedshort-term/temporary use only

Jensen and Haidari systematic reviews

Prophylactic NPWT in prosthetic breast reconstruction: Meta-analysis favored NPWT for reduced mastectomy flap necrosis and overall wound complications; consider covered where evidence supports reduced flap necrosis in prosthetic breast reconstruction

Meta-analysis of comparative studies cited

Coverage-relevant evidence summaries

Findings relevant to coverage decisions:

STSG fixation and bolster evidence: Cohort and retrospective studies report higher graft survival proportions and lower hematoma and infection rates with NPWT used as a bolster for STSGs compared with conventional fixation; some series report graft survival ~97% at first dressing change

Li et al and related studies report high graft-survival and reduced complications

ciNPWT for arthroplasty and spinal fusion: Systematic reviews/meta-analyses indicate ciNPWT may reduce SSI risk in revision total joint arthroplasty and after spinal fusion but may increase non-infectious complications (eg, blistering) in primary TKA

Ailaney et al and Lambrechts et al findings

Prophylactic NPWT after pancreatectomy: Meta-analysis of RCTs found no significant reduction in SSI with prophylactic NPWT after pancreatectomy; routine use is not supported by current evidence

Lenet et al 2022

NPWT with instillation (VeraFlo): Preclinical and clinical data suggest instillation with saline or antiseptic may improve granulation quality and reduce OR visits and LOS for infected wounds; randomized data show no clear superiority of antiseptic over normal saline

Leung porcine model; Kim et al clinical studies

Evidence limitations: Most positive findings derive from cohort, retrospective, and small RCTs with heterogeneous populations; study limitations and inconsistent quality frequently noted, indicating need for larger, high-quality RCTs before definitive conclusions for many indications

Multiple chunks describe limitations and heterogeneity

Continuation and extension criteria

Coverage for NPWT is provided to initiate healing of specified problem wounds; continuation beyond standard limits requires specific documentation.

Continuation requirements: For each subsequent month of NPWT, the medical record must include updated quantitative wound measurements (length, width/surface area, or depth), documentation of changes applied to promote healing, amount of exudate, presence of granulation/necrosis, and other concurrent measures; supplier should obtain monthly treating clinician assessment to determine continued medical necessitymonthly

Initial inpatient start date must be documented if therapy began inpatient; excess canister quantities require explicit justification in the record

Extension beyond 4 months: When NPWT therapy exceeds 4 months on the most recent wound, individual consideration for one additional month at a time may be requested via appeals with contemporaneous treating physician documentation explaining special circumstances requiring extension; vague statements (eg, 'doing well, want to continue until healed') are insufficient>4 months

Detailed contemporaneous documentation required for each requested month

Negative pressure wound therapy (NPWT) applied prophylactically at the time of surgery is considered part of the surgical procedure and is incidental to the surgery; consequently, prophylactic NPWT for surgical care is not separately reimbursed.

NPWT is contraindicated in several wound conditions. Contraindications include cancer present in the wound; inadequately debrided wounds or the presence of necrotic tissue with eschar when debridement is not attempted; untreated osteomyelitis or sepsis within the vicinity of the wound; presence of a fistula to an organ or body cavity near the wound; untreated coagulopathy; and active local skin infection or gangrene when necrotic eschar is not being debrided.

Routine prophylactic NPWT for cesarean delivery incisions in low-risk women is not supported by compelling randomized trial evidence and economic modeling suggests standard dressings are preferred for low-risk patients. Meta-analyses and cost-effectiveness studies indicate potential benefit mainly in higher-risk, mostly obese cohorts; absent strong trial data for routine use in low-risk cesarean patients, prophylactic NPWT should not be assumed to be covered.

Randomized trial data do not support the use of NPWT to reduce incisional surgical-site infection following open resection of intra‑abdominal malignancies. A randomized phase II trial found no significant difference in superficial or deep incisional SSI rates between NPWT and standard dressing groups, and the authors concluded NPWT cannot currently be recommended to decrease infectious complications in this population.

Available guidance (WPATH Standards of Care) and several UpToDate reviews do not mention NPWT for postoperative transgender surgeries and no evidence base is presented in those sources to support routine NPWT in these procedures. Therefore NPWT is not established for this indication in the cited guidance and reviews.

The literature does not clearly support NPWT as definitive therapy for fracture‑related infections (FRI). Systematic reviews found no comparative studies and only low-level case series/reports; authors recommend early definitive soft tissue coverage (eg, local or free flap) when feasible and consider NPWT only as a short-term temporizing measure until definitive coverage can be performed.

Within the excerpted material there are no additional explicit exclusions beyond those listed in the policy appendix and body; the document does not provide further standalone exclusion statements in this selection.

Evidence for NPWT in fracture‑related infections is limited and heterogeneous; current reviews do not recommend NPWT as a definitive curative therapy for infected osteosynthesis. When used, NPWT is generally considered a temporary measure to manage soft tissue until early definitive coverage (eg, flap) can be achieved rather than a substitute for prompt surgical reconstruction.

Meta-analyses and randomized trials do not demonstrate a significant reduction in surgical site infection with routine prophylactic NPWT after pancreatectomy. A pooled analysis of randomized trials found no significant difference in SSI rates between NPWT and control, and the authors concluded insufficient evidence exists to support routine prophylactic NPWT for pancreatectomy incisions.

The policy lists multiple contraindications that make provision of NPWT pumps and supplies medically inappropriate. NPWT pump and supplies are not medically necessary when contraindications are present, including necrotic tissue with eschar if debridement is not attempted, untreated osteomyelitis near the wound, cancer present in the wound, an open fistula to an organ or body cavity in the wound vicinity, active local skin infection, or untreated coagulopathy.

The policy identifies specific devices and uses considered experimental, investigational, or not covered. Examples include non‑powered mechanical NPWT devices (e.g., SNaP), single‑use NPWT devices for all indications where not otherwise supported, VeraFlo (instillation) for wound healing in some contexts, and use of wound VAC for full‑thickness burns; these device‑or indication‑specific items are listed as not established and therefore typically not covered.

The document highlights broad evidence limitations: numerous systematic reviews and technology assessments report a lack of high‑quality randomized trials across many wound types, comparative trials of NPWT systems are lacking, and results are often derived from small, heterogeneous studies. For many indications the certainty of evidence is low or very low, limiting confidence in routine coverage decisions.

The use of NPWT to reduce surgical site infection or prevent wound dehiscence on primarily closed incisions remains uncertain. Cochrane and other systematic reviews that pooled multiple trials concluded evidence is low or very‑low certainty and does not consistently demonstrate reduced SSI, dehiscence, or other key outcomes; therefore routine prophylactic application on primary closure wounds is not supported by robust trial data.

Randomized trial evidence specifically addressing NPWT to decrease SSI after open resection of intra‑abdominal malignancies did not show benefit; the cited phase II RCT found no significant differences in superficial or deep incisional SSI between NPWT and standard dressing, indicating NPWT is not supported for this specific purpose based on current RCT data.

For open fractures the evidence does not show clear clinical benefit and may not be cost‑effective in some settings. Cochrane and economic analyses found no consistent improvement in wound healing proportions at 6 weeks and moderate to very low certainty evidence for infection outcomes; one trial suggested NPWT was unlikely to be cost‑effective in the UK setting.

Evidence for NPWT in pilonidal disease is limited and inconclusive. Published reports are mainly case series and retrospective analyses with small samples; investigators conclude that higher‑quality randomized controlled trials are needed before drawing firm practice conclusions.

Some clinical reviews and authoritative resources (eg, UpToDate entries, selected burn reviews) do not list VAC/NPWT as a routine management option for certain burn care contexts. Although NPWT can be useful as a skin‑graft bolster and in select burn applications, routine inclusion in burn care guidance is limited by sparse or mixed evidence in some areas.

Prophylactic NPWT after pancreatectomy is not supported as a routine measure by current randomized trial meta‑analysis evidence. The pooled RCT data found no statistically significant reduction in SSI with NPWT versus control, and the authors advise against routine use absent stronger evidence or clear high‑risk indications.

Billing and Coding

Covered CPT CodesCPTCovered

96574	Debridement of premalignant hyperkeratotic lesion(s) followed with photodynamic therapy
97605	Negative pressure wound therapy; total wound(s) surface area <= 50 sq cm
97606	Negative pressure wound therapy; total wound(s) surface area > 50 sq cm
97602	Removal of devitalized tissue from wound(s), non-selective debridement, without anesthesia, per session

CPT Codes Not Covered for Indications ListedCPTNot Covered

97607	Negative pressure wound therapy utilizing disposable, non-durable medical equipment, total wound(s) surface area <= 50 sq cm
97608	Negative pressure wound therapy utilizing disposable, non-durable medical equipment, total wound(s) surface area > 50 sq cm

Other Related CPT CodesCPT

11000-11047	Excision - debridement of skin, subcutaneous tissue, muscle and/or fascia, bone
15733	Muscle, myocutaneous, or fasciocutaneous flap; head and neck
15756	Free muscle or myocutaneous flap with microvascular anastomosis
15757	Free skin flap with microvascular anastomosis

Covered HCPCS CodesHCPCSCovered

A6550	Wound care set for negative pressure wound therapy electrical pump, includes all supplies and accessories
A9272	Wound suction, disposable, includes dressing, all accessories and components, any type, each
E2402	Negative pressure wound therapy electrical pump, stationary or portable
K0743	Suction pump, home model, portable, for use on wounds
K0744	Absorptive wound dressing for use with suction pump, home model, pad size <= 16 sq in
K0745	Absorptive wound dressing for use with suction pump, home model, pad size >16 and <=48 sq in
K0746	Absorptive wound dressing for use with suction pump, home model, pad size >48 sq in

Other Related HCPCS CodesHCPCS

A7000	Canister, disposable, used with suction pump, each
C7500	Debridement, bone including manual preparation and insertion of deep drug-delivery device(s), first 20 sq cm or less

ICD-10 Codes Covered When Selection Criteria MetICD-10Covered

E10.40-E10.49	Diabetes with neurological manifestations (chronic neuropathic ulcers)
E11.40-E11.49	Diabetes with neurological manifestations (chronic neuropathic ulcers)
E13.40-E13.49	Diabetes with neurological manifestations (chronic neuropathic ulcers)
E10.51-E10.59	Diabetes with peripheral circulatory disorders (chronic ulcers)
E11.51-E11.59	Diabetes with peripheral circulatory disorders (chronic ulcers)
E13.51-E13.59	Diabetes with peripheral circulatory disorders (chronic ulcers)
I70.231-I70.269	Atherosclerosis of native arteries of extremities with ulceration or gangrene
I70.261	Atherosclerosis of native arteries
I73.9	Peripheral vascular disease, unspecified
I83.001-I83.029	Varicose veins of lower extremities with ulcer

1–10 of 13

1/2

ICD-10 Codes Contraindicated / Not Appropriate for NPWTICD-10Not Covered

C00.0-C96.9	Malignant neoplasms (cancer present in wounds)
D00.00-D09.9	Carcinoma in situ / pre-malignant neoplasms
I96	Gangrene, not elsewhere classified (necrotic tissue with eschar if debridement not attempted)
L08.9	Local infection of skin and subcutaneous tissue, unspecified
M86.00-M86.9	Acute, chronic, or unspecified osteomyelitis
T20.30x+-T20.39x+ T20.70x+-T20.79x+	Third degree burns face, head and neck (necrotic tissue with eschar if debridement not attempted)
T21.30x+-T21.39x+ T21.70x+-T21.79x+	Third degree burns trunk
T22.30x+-T22.399x+ T22.70x+-T22.799+	Third degree burns upper limb
T23.301+-T23.399+ T23.701+-T23.799+	Third degree burns wrist and hand
T24.301+-T24.399+ T24.701+-T24.799+	Third degree burns lower limb

1–10 of 13

1/2

ICD-10 Codes - Additional Relevant Injury/Burn CodesICD-10

S02.0xx+-S02.92x+	Fractures of skull and facial bones
S12.000+-S12.691+	Fractures of neck
S22.000+-S22.9xx+	Fractures of thorax
S32.000+-S32.9xx+	Fractures of lumbar spine and pelvis
S42.001+-S42.92x+	Fractures of shoulder and upper arm
S52.001+-S52.009+	Fractures of forearm
S62.001+-S62.92x+	Fractures of wrist and hand
S72.001+-S72.466+	Fractures of femur

ICD-10 Codes - Presence of Prosthesis/Implant/TransplantICD-10

Z90.10-Z90.13	Acquired absence of breast and nipple
Z94.0	Kidney transplant status
Z95.810-Z95.818	Presence of other cardiac implants and grafts
Z96.641-Z96.649	Presence of artificial hip joint
Z96.651-Z96.659	Presence of artificial knee joint
Z98.82	Breast implant status

Billing / Documentation Requirementmixed

Billing Diagnosis Code

When billing for NPWT, an ICD diagnosis code specific to the wound being treated must be included on each claim for equipment and supplies (ICD-10 codes preferred).

HCPCS Codes Covered if Selection Criteria MetHCPCSCovered

A6550	Wound care set for negative pressure wound therapy electrical pump, includes all supplies and accessories
A9272	Wound suction, disposable, includes dressing, all accessories and components, any type, each
E2402	Negative pressure wound therapy electrical pump, stationary or portable
K0743	Suction pump, home model, portable, for use on wounds
K0744	Absorptive wound dressing for use with suction pump, home model, pad size <= 16 sq in
K0745	Absorptive wound dressing for use with suction pump, home model, pad size >16 and <=48 sq in
K0746	Absorptive wound dressing for use with suction pump, home model, pad size >48 sq in

Other HCPCS RelatedHCPCS

A7000	Canister, disposable, used with suction pump, each
C7500	Debridement, bone including manual preparation and insertion of deep drug-delivery device(s), first 20 sq cm or less

HCPCS - Disposable Suction Dressings (Examples)HCPCS

A9272

Disposable wound suction dressing, each

Billing Diagnosis Code Requirementmixed

ICD-10 on Claim

An ICD-10 diagnosis code specific to the wound being treated must be included on each claim for NPWT equipment and related supplies.

ICD-10 Codes Relevant to Coverage / ContraindicationsICD-10

T22.60x+-T22.699+	Burns or corrosion of second degree of shoulder and upper limb (partial-thickness)
T22.299+	Burns or corrosion of second degree, related codes
T23.201+-T23.299+	Burns or corrosion of second degree of wrist and hand (partial-thickness)
T23.601+-T23.699+	Burns or corrosion of second degree, wrist and hand variants
T23.301+-T23.399+	Third degree burns wrist and hand (presence of necrotic tissue with eschar if debridement not attempted)
T23.701+-T23.799+	Third degree burns wrist and hand range
T22.30x+-T22.399x+ T22.70x+-T22.799+	Third degree burns upper limb (necrotic tissue/eschar)
T23701+	(Included in third-degree burn wrist/hand block)
Z96.641-Z96.649	Presence of artificial hip joint

ICD-10 Codes - Extended Contraindications / Third Degree BurnsICD-10Not Covered

T20.30x+-T20.39x+ T20.70x+-T20.79x+	Third degree burns face, head and neck
T21.30x+-T21.39x+ T21.70x+-T21.79x+	Third degree burns trunk
T22.30x+-T22.399x+ T22.70x+-T22.799+	Third degree burns upper limb
T23.301+-T23.399+ T23.701+-T23.799+	Third degree burns wrist and hand
T24.301+-T24.399+ T24.701+-T24.799+	Third degree burns lower limb
T25.311+-T25.399+ T25.711+-T25.799+	Third degree burns lower limb variants
T30.0-T30.4	Burn and corrosion of unspecified body region (third degree burns)

ICD-10 Codes - Contraindicated ConditionsICD-10Not Covered

C00.0-C96.9	Malignant neoplasms in wounds
D00.00-D09.9	Carcinoma in situ / pre-malignant neoplasms
I96	Gangrene, not elsewhere classified
L08.9	Local infection of skin and subcutaneous tissue
M86.00-M86.9	Osteomyelitis (untreated)
T81.83xA-T81.83xS	Persistent postoperative fistula

ICD-10 Codes - Injury / Fracture RangesICD-10

S02.0xx+-S02.92x+	Fractures of skull and facial bones ranges
S12.000+-S12.691+	Fractures of neck ranges
S22.000+-S22.9xx+	Fractures of thorax ranges
S32.000+-S32.9xx+	Fractures of lumbar spine and pelvis ranges
S42.001+-S42.92x+	Fractures of shoulder and upper arm ranges
S52.001+-S52.009+	Fractures of forearm ranges
S62.001+-S62.92x+	Fractures of wrist and hand ranges
S72.001+-S72.466+	Fractures of femur ranges

ICD-10 - Other Relevant CodesICD-10

Z90.10-Z90.13	Acquired absence of breast and nipple
Z94.0	Kidney transplant status
Z95.810-Z95.818	Presence of other cardiac implants and grafts
Z96.651-Z96.659	Presence of artificial knee joint
Z98.82	Breast implant status

Billing Diagnosis Code Requirement (Operational)mixed

ICD-10 on Claim

An ICD-10 diagnosis code specific to the wound being treated must be included on each claim for NPWT equipment and related supplies; supplier must obtain clinician assessment of wound healing progress monthly.

ICD-10 Codes — Extended List / ContraindicationsICD-10Not Covered

T22.299+	Burns or corrosion of second degree related codes
T22.60x+-T22.699+	Second degree burns of shoulder and upper limb (partial-thickness)
T23.201+-T23.299+ T23.601+-T23.699+	Second degree burns of wrist and hand (partial-thickness) ranges
T23.301+-T23.399+ T23.701+-T23.799+	Third degree burns wrist and hand ranges (contraindicated when necrotic tissue/eschar present and debridement not attempted)
T23701+	Included in third-degree burn wrist/hand block
Z96.641-Z96.649	Presence of artificial hip joint (listed for post-surgical context)

ICD-10 Contraindicated Burn Codes — AdditionalICD-10Not Covered

T20.30x+-T20.39x+ T20.70x+-T20.79x+	Third degree burns face, head and neck
T21.30x+-T21.39x+ T21.70x+-T21.79x+	Third degree burns trunk
T22.30x+-T22.399x+ T22.70x+-T22.799+	Third degree burns upper limb
T24.301+-T24.399+ T24.701+-T24.799+	Third degree burns lower limb
T25.311+-T25.399+ T25.711+-T25.799+	Third degree burns lower limb variants

Operational Billing Notemixed

Documentation

When billing for NPWT include wound-specific ICD-10 code and maintain documentation of wound measurements and exudate; supplier to obtain clinician assessment monthly to support continued medical necessity.

Billing Diagnosis Code Requirementmixed

ICD-9/ICD-10 on Claim

When billing for NPWT, an ICD diagnosis code specific to the wound being treated must be included on each claim for the equipment and related supplies. (ICD-10 codes preferred for current claims.)

Exudate volume threshold for canister allowance> 90 ml per day

SSI rate threshold for cost-benefit14% (standard dressing preferred when SSI ≤14%)

Device price threshold for cost-benefit$192 (prophylactic NPWT can be cost-beneficial if priced below $192)

BMI thresholds referenced in economic analyses≥ 30 kg/m2 and ≥ 35 kg/m2 subgroup

NPWT pressure settings referenced-125 mmHg common; -75 mmHg in some trials

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required for NPWT Devices and Supplies

Prior authorization is required when billing for NPWT pumps and related supplies. Coverage is contingent on meeting the medical necessity criteria in this policy (including required prior wound therapy, debridement when indicated, and documentation of wound measurements and progress). Suppliers should verify payer-specific prior authorization processes before initiating therapy.

Prior authorization required for NPWT devices and supplies when billed to Aetna (policy 0334).
Coverage contingent on meeting the Medical Necessity and Continued Medical Necessity criteria in the policy.
Suppliers should obtain monthly clinician verification of wound progress to support continued coverage.

Prior Authorization

Prior Authorization: Document Appropriate ICD-10 Codes

When requesting prior authorization, providers must submit appropriate ICD-10 diagnosis codes that describe the wound being treated and demonstrate the wound is appropriate for NPWT and not contraindicated.

Include an ICD-10 code specific to the wound (as required on each claim).
If an ICD-10 code listed in the contraindicated group (see contraindications callout) is present, document steps taken (e.g., debridement, treatment of osteomyelitis) before considering NPWT.

Prior Authorization

Prior Authorization for Prophylactic Incisional NPWT

Prior authorization is suggested for prophylactic incisional NPWT (iNPWT) applied to closed laparotomy or cesarean incisions, particularly when used outside high-risk populations. Provide documentation of patient risk factors and evidence supporting use.

For prophylactic iNPWT after cesarean delivery, document SSI risk factors (e.g., obesity, BMI strata) and cite trial/economic evidence if available.
Economic models favor standard dressing for low-risk patients; prior authorization should reflect clinical and economic justification.

Prior Authorization

Prior Authorization for Prophylactic/Incisional NPWT (Consider)

Given mixed evidence for prophylactic/incisional NPWT across procedures, consider prior authorization to ensure appropriate patient selection and documentation of risk profile and expected benefit.

Use prior authorization to capture indication (prophylactic vs therapeutic), patient risk factors, and relevant supporting literature.
Provide procedure type, wound characteristics, and rationale for prophylactic application.

Prior Authorization

PA Considerations for ciNPWT and Prophylactic NPWT

Prior authorization may be reasonable for closed-incision NPWT (ciNPWT) when used in high-risk or revision total hip/knee arthroplasty or other high-risk surgical populations where evidence suggests reduced SSI, but routine use in low-risk cases is not supported.

Document patient risk factors (e.g., revision surgery, obesity, prior SSI) when submitting PA requests for ciNPWT.
Include references to RCTs or systematic reviews showing benefit in similar high-risk populations when available.

Note

Prior Authorization Status and Administrative Guidance

Policy indicates the standard Aetna Clinical Policy Bulletin framework applies. Specific PA requirements and affected codes may be provided via payer administrative channels; check the payer's provider portal for up-to-date PA forms and code lists.

Prior authorization status: PA required or suggested for certain prophylactic/ciNPWT uses; confirm via Aetna prior authorization resources.
Affected HCPCS/CPT/ICD-10 codes and PA forms are managed through payer administrative guidance.

Denial Risk

NPWT Not Medically Necessary with Necrosis/Untreated Osteomyelitis

NPWT is not medically necessary when necrotic tissue with eschar is present and debridement has not been attempted, or when untreated osteomyelitis exists in the vicinity of the wound. Such situations are contraindications to NPWT until appropriately managed.

Do not initiate NPWT if necrotic tissue with eschar is present and debridement has not been performed.
Untreated osteomyelitis adjacent to the wound is a contraindication; document active treatment plan if present.

Denial Risk

Contraindicated ICD-10 Diagnoses for NPWT

Certain ICD-10 diagnoses are contraindicated for NPWT and must be identified and documented. Presence of these diagnoses may preclude coverage unless corrective treatment has been undertaken and documented.

Contraindicated ICD-10 diagnoses include malignant neoplasms involving the wound (C00–C96; D00–D09), gangrene (I96) when due to necrotic tissue with eschar without debridement, local skin infection (L08.9), untreated osteomyelitis (M86.0–M86.9), persistent postoperative fistula (T81.83xA–T81.83xS), and codes for third-degree burns where eschar is present and debridement not attempted (T20–T25 series).
If a contraindicated diagnosis is present, provide documentation of interventions (e.g., debridement, treatment of infection/osteomyelitis) before reconsideration.

Denial Risk

Insurer Stance: Do Not Routinely Cover Prophylactic NPWT Absent Compelling Evidence

Absent compelling randomized trial results for routine prophylactic NPWT after cesarean delivery, payers should not routinely cover prophylactic NPWT for low-risk patients; coverage may be considered for high-risk patients with documented justification.

Economic and editorial analyses advise against routine insurer coverage for prophylactic NPWT after cesarean in low-risk populations.
For high-risk cesarean patients (e.g., BMI ≥ 35 kg/m2, other risk factors), provide RCT or subgroup evidence and economic rationale with PA.

Note

Economic Model: Standard Dressing Preferred for Low-Risk Patients

Economic analyses indicate standard postoperative dressing is the preferred strategy for many low-risk patients (e.g., post-cesarean) unless SSI risk is sufficiently high or NPWT is priced to be cost-beneficial. Use economic justification in PA submissions when arguing for prophylactic NPWT.

Decision-analytic models favor standard dressing for SSI rates ≤ 14 %; NPWT may be cost-beneficial above that threshold depending on efficacy and price.
Include cost-effectiveness data or local SSI risk estimates when requesting PA for prophylactic use.

Denial Risk

NPWT Not Effective to Reduce SSI After Open Resection of Intra-abdominal Malignancy — Denial Risk

For some populations (e.g., open resection of intra-abdominal malignancy), high-quality trial evidence does not support NPWT to reduce surgical site infections; coverage for these indications may be denied.

Randomized trial evidence in resection of intra-abdominal malignancy did not show a reduction in incisional SSI with NPWT versus standard dressing.
Provide strong clinical rationale and supportive data if requesting NPWT for these indications; anticipate denial risk.

Denial Risk

Evidence Uncertainty May Trigger Denial or PA Review

Evidence uncertainty regarding NPWT versus standard dressings for key outcomes (SSI, dehiscence, re-operation, cost-effectiveness) may trigger prior authorization review or denial. Use PA to provide detailed clinical and evidentiary justification for uncertain indications.

Uncertain evidence domains include prophylactic use in low-risk patients, many routine closed incisions, and fracture-related infection (FRI) management.
When evidence is low or very-low certainty, include patient-specific risk factors and available supportive studies in the PA submission.

Note

No Explicit Prior Authorization or Denial Triggers Stated — Case-by-Case Review

The policy does not specify explicit prior authorization or denial trigger codes for every indication; device selection recommendations are consensus-based. Providers should expect case-by-case review for non-standard uses.

No exhaustive PA code list in-policy; consult payer administrative resources for up-to-date PA requirements.
Non-standard or emerging uses (e.g., widespread prophylactic ciNPWT) will often require individualized PA and supporting evidence.

Denial Risk

Insufficient Evidence for NPWT in Fracture-Related Infection (FRI)

For fracture-related infection (FRI) and infected osteosynthesis, current evidence is insufficient to support definitive use of NPWT as treatment; PA may be required and denial is possible in the absence of strong supporting data.

Systematic reviews found low-level, high-bias evidence and no comparative trials of NPWT versus dressings in FRI.
If requesting NPWT for FRI, include detailed operative, microbiologic, and wound-healing plans and rationale for temporary versus definitive use.

Denial Risk

Extension Beyond 4 Months: Denial Risk Without Detailed Documentation

Requests to extend NPWT beyond 4 months for a given wound carry a higher risk of denial and require detailed, contemporaneous monthly documentation; extensions are considered one month at a time via appeals with specific clinical justification.

NPWT beyond 4 months requires individual consideration with physician contemporaneous records for each additional month requested.
Vague statements (e.g., 'doing well, want to continue until healed') are insufficient to justify an extension.

Note

Coverage Enforcement and Administrative Context

Clinical Policy Bulletins (CPBs) guide benefit administration; failure to follow policy criteria, PA processes, and documentation requirements may result in denial or non-payment.

Coverage enforcement context: adherence to CPB criteria and payer administrative procedures is required for claim approval.
Providers and suppliers should consult Aetna CPB resources and payer portals for submission instructions and appeals processes.

Documentation Required

Documentation Frequency and Required Elements

Documentation must include initial and monthly wound evaluation, care provided, and quantitative wound measurements (length, width/surface area, depth) and changes in wound characteristics to support initial authorization and continued coverage.

At initiation: treating physician statement of wound condition, measurements, prior treatments, and plan addressing debridement, nutrition, support surfaces, and incontinence control.
Monthly: updated wound measurements, changes in exudate, granulation/necrotic tissue, dressing types and frequency, and clinician assessment of healing progress.

Documentation Required

Suggested Clinical Documentation Elements

Suggested clinical documentation elements to include with PA and for medical records: wound type and location, infection status, debridement attempts, prior therapies tried, device type (s-NPWT vs t-NPWT), and rationale for chosen therapy.

Specify wound etiology (pressure ulcer stage, neuropathic, venous/arterial insufficiency, post-surgical incision, STSG site, fasciotomy, traumatic/open fracture).
Document infection status, recent debridement, vascular status, comorbidities (e.g., diabetes), and prior local/regional treatments.

Documentation Required

Clinical Justification Should Reference Relevant Evidence

Clinical justification for non-standard or controversial NPWT uses should reference relevant randomized trials, systematic reviews, economic analyses, or consensus statements as support and explain how the patient matches the studied populations.

When supporting prophylactic or off-label NPWT, cite pertinent RCTs, meta-analyses, or economic models and explain applicability to the patient.
Include subgroup data (e.g., BMI strata, revision arthroplasty) if relying on subgroup benefits to justify therapy.

Documentation Required

Clinical Indication and Prior Treatment Documentation Required

Documentation for PA should include clinical indication and prior treatment documentation: prior dressings/AMWT attempts, debridement history, off-loading or support surface use, and any surgical interventions performed.

For home-setting chronic wounds, show a complete wound therapy program was tried or considered prior to NPWT.
For STSG bolster or adjunct uses, document prior graft preparation, timing, and rationale for NPWT bolster application.

Documentation Required

Suggested Documentation Elements for Prophylactic/Incisional NPWT

Suggested documentation elements for prophylactic NPWT submissions include patient risk stratification, trial evidence or economic analysis references, and expected outcomes (e.g., SSI reduction) tied to the patient's risk profile.

Report BMI, comorbidities, procedure type, and baseline SSI risk estimates when requesting prophylactic NPWT.
Include device type, duration intended, and monitoring plan.

Documentation Required

Documentation of Evidence and Wound Characteristics

Document wound characteristics and device details when evidence is being used to support therapy choice (s-NPWT vs t-NPWT): include wound size, depth, amount/type of exudate, and prior response to other modalities.

State wound dimensions and exudate volume to justify canister needs and device selection (stationary pumps for high-volume drainage).
If citing RCT outcomes, include study population, device used, and duration to demonstrate applicability.

Documentation Required

Study Support and Device/Duration Details Should Be Provided

When submitting for NPWT in special or emerging indications, include study support and device/duration details: randomized trial citations, device model, pressure settings, dressing-change frequency, and treatment duration used in supportive studies.

Provide copies or citations of RCTs or meta-analyses used to justify the request and summarize key outcomes (SSI reduction, graft take, time to closure).
Include planned NPWT regimen details to match evidence (e.g., days of postoperative application for prophylactic use).

Documentation Required

Supporting Clinical Documentation to Include Outcomes and Operational Metrics

Supporting clinical documentation for claims and continuation should include graft survival rates, complications, dressing-change timing, hospital length of stay impacts, and any economic or quality-of-life data when applicable.

For STSG bolster or complex reconstructions, include graft take metrics and re-operation rates.
For ciNPWT or prophylactic uses, provide SSI rates, re-admission, and re-operation outcomes where available.

Documentation Required

Required Documentation for Billing and Continued Coverage

Required documentation for billing and continuation includes detailed history, prior treatments, session lengths, dressing types/frequency, precise monthly wound measurements, and clinician assessments that justify ongoing supplies and pump rental.

Suppliers must obtain monthly treating clinician assessments of wound healing progress (verbal or written) to justify continued billing.
When billing for quantities greater than policy maxima (e.g., >15 dressing kits or >10 canisters), include explicit justification in the medical record.

Note

Documentation and Review Resources

The policy contains review history and links to resources; providers should consult these review resources and payer guidance when preparing PA requests or appeals.

Use the CPB review history and additional information links for appeals and submission references.
Contact payer provider services or portal for current PA forms, code lists, and submission instructions.

Documentation Required

Home-Setting Prerequisites Before NPWT

Before initiating NPWT in the home setting, document that a complete wound therapy program has been implemented or considered and ruled out, and that wound care support is available to supervise dressing changes and wound assessment.

Home-setting prerequisites: evidence of comprehensive wound care program, clinician oversight, plan for dressing changes, and monthly documentation schedule.
Demonstrate access to supplies, caregiver support or home health services when applicable.

Step Therapy

Therapy Sequencing Considerations

Therapy sequencing considerations: document prior use of conservative measures and advanced moist wound therapy (AMWT); NPWT is generally considered after or compared against AMWT for certain wounds (e.g., diabetic foot ulcers).

For chronic ulcers, show at least 30 days of wound presence and that a wound therapy program (including AMWT) was tried or considered prior to NPWT.
Include details of off-loading, compression, and other adjunctive measures attempted.

Step Therapy

Step-Up to NPWT After Standard Care or Conservative Alternatives

Clinical practice often employs a step-up approach: consider standard dressings or non-commercial negative-pressure constructs first for some indications; escalate to commercial NPWT when these measures fail or when trial evidence supports NPWT benefit.

Evidence shows some low-cost alternatives (e.g., GSUC or 'home-made' NPWT) can provide comparable outcomes in select settings (e.g., STSG bolster); document prior use where applicable.
Document why a commercial NPWT device is required if conservative alternatives were not tried or are contraindicated.

Note

Device Selection Pathway: s-NPWT vs t-NPWT

Device selection pathway: when NPWT is appropriate, consider single-use (s-NPWT) devices as first-line for eligible smaller wounds and ambulatory patients; use traditional/portable (t-NPWT) systems for larger, complex, or high-exudate wounds. Document the rationale for device selection.

Select s-NPWT for ambulatory, smaller wounds when supported by evidence and patient needs.
Select t-NPWT or stationary pumps for large wounds, high-volume drainage, or when canister capacity is required.

Step Therapy

Consider Conservative / Low-Cost NPWT Alternatives Before Commercial Systems

Consider conservative or low-cost NPWT alternatives (e.g., GSUC or non-commercial negative pressure constructs) before commercial NPWT for some indications; randomized and comparative data support comparable outcomes in select uses such as STSG bolster.

If a low-cost alternative was used successfully, document outcomes and rationale for continuing or transitioning to commercial NPWT.
Cost comparisons and trial data may be used in PA submissions to justify device choice.

Note

Instillation Therapy (NPWT with Instillation) as an Adjunct for Infected Wounds

For infected wounds requiring operative care, NPWT with instillation (VeraFlo) may be used as an adjunct; documentation should include evidence from studies suggesting faster wound preparation and fewer operative visits versus standard NPWT alone.

When requesting NPWT with instillation, include documentation of infection status, prior debridements, instillation solution chosen, dwell times, and supporting study references.
Specify intended endpoints (e.g., fewer OR visits, shorter time to final surgical procedure) and monitoring plan.

Billing Rule

Monthly Supplier-Clinician Verification Required for Continued Billing

Monthly supplier-clinician verification is required to justify continued equipment and supplies. The supplier must obtain the treating clinician's monthly assessment of wound healing progress (verbal or written) based on documented wound measurements.

Supplier should document that monthly clinician assessments were obtained and that wound measurements demonstrate progress as required in the policy.
Medical records may be requested to corroborate the supplier's statements supporting continued billing.

Background and Evidence Summary

Background: NPWT applies controlled subatmospheric pressure to a wound using a pump, tubing and a specialized dressing to promote granulation and remove exudate. It has been used for both chronic and certain acute wounds to increase local vascularity, reduce edema, and evacuate wound fluid; however, many systematic reviews have raised concerns about the overall quality and consistency of the evidence across indications.

Evidence-based coverage considerations

Evidence summary & contextual considerations from the policy document (background for coverage decisions)

Evidence base summary: Numerous systematic reviews and technology assessments question the overall quality of evidence for NPWT across indications; while some RCTs (eg, Blume 2008 for diabetic foot ulcers) show benefit, many reviews (AHRQ, Cochrane, NICE) identify research gaps and call for standardized larger RCTs

See cited systematic reviews and assessments

Device and comparative trial considerations: Comparative device trials (eg, SNaP vs VAC) demonstrate noninferiority in selected wounds but limitations (lack of blinding, imbalanced groups, manufacturer funding) reduce certainty; single-use device evidence is accumulating but not definitive for all indications

Armstrong et al and related device literature

Implication for coverage: Given heterogeneity and variable quality of evidence, coverage decisions should be indication-specific, require documentation of prior conservative measures and wound metrics, and consider device selection (s-NPWT vs t-NPWT) based on wound complexity and care setting

Policy integrates evidence summaries into coverage criteria and documentation requirements

Coverage considerations and conditional evidence: multiple systematic reviews, Cochrane updates, and technology assessments show mixed results across indications. Some trials and reviews report reduced surgical‑site complications in select high‑risk incisions and improved graft take for skin grafts, while many other contexts lack high‑quality RCT data or show no clear benefit. Device selection (single‑use versus traditional) and cost‑effectiveness depend on clinical setting, patient risk factors, and device price thresholds identified in economic analyses.

Indication‑specific evidence summaries: NPWT shows benefit as a bolster for split‑thickness skin grafts and has supportive but limited evidence in burns and closed groin or vascular incisions (meta‑analyses showing reduced SSI in some settings). Prophylactic incisional NPWT after cesarean delivery shows reduced SSI in mostly obese populations, but routine use in low‑risk patients is not supported; closed‑incision NPWT demonstrates mixed quality evidence across surgical specialties.

Additional indication‑specific evidence and device considerations: randomized and comparative trials of single‑use NPWT (s‑NPWT) versus traditional NPWT (t‑NPWT) show promising results for some wound types (eg, diabetic and venous leg ulcers), and economic modeling suggests potential payer savings in selected situations. Nonetheless, heterogeneity of studies and device types limits broad generalization, and higher‑quality trials comparing devices and indications are still needed.

Definitions and Terms

Pressure ulcer staging definitions

Stage IIntact skin with non-blanchable redness of a localized area, usually over a bony prominence

Stage IIPartial-thickness loss of dermis presenting as a shallow open ulcer with red or pink wound bed, or intact/open ruptured serum-filled blister

Stage IIIFull-thickness tissue loss; subcutaneous fat may be visible but bone, tendon or muscle are not exposed; slough may be present

Stage IVFull-thickness tissue loss with exposed bone, tendon or muscle; slough or eschar may be present

UnstageableFull-thickness tissue loss in which base of ulcer is covered by slough and/or eschar so depth cannot be determined

Suspected deep tissue injuryPurple or maroon localized area of discolored intact skin or blood-filled blister from damage of underlying soft tissue

NPWT definition

DefinitionControlled application of subatmospheric pressure to a wound using an electrical pump, tubing, foam dressing and occlusive seal to promote healing and collect drainage in a canister

ComponentsSystem includes pump, dressing sets (foam/porous dressing and occlusive film), tubing and collection canister

MechanismPromotes granulation, reduces edema, removes exudate and may decrease bacterial burden

Single-use / non-powered NPWT definition and comparison notes

DefinitionSingle-use/non-powered NPWT refers to smaller, often canister‑free or disposable portable systems intended for single-patient use (eg, PICO, SNaP)

Comparative notesEvidence for single‑use and non-powered devices is accumulating but comparative trials are limited; selection depends on wound size, exudate amount, and care setting

Coverage considerationSome single‑use devices are considered experimental/investigational for all indications in this policy and may not be covered under plans excluding supplies

NPWTi / NPWTi-d (instillation) definition

DefinitionNPWTi / NPWTi-d refers to NPWT combined with intermittent instillation of a topical solution into the wound with a dwell time before resuming negative pressure

Device distinctionNPWTi-d systems provide timed, volumetric control of instilled solution and automated cycles (eg, V.A.C. VeraFlo) versus older continuous-instillation methods

Clinical noteEvidence is promising for infected/complex wounds but limited; optimal instillation solution and settings remain uncertain

Prophylactic incisional NPWT (pNPWT) definition

DefinitionProphylactic incisional NPWT (pNPWT) is application of negative pressure over a closed surgical incision to prevent surgical site complications and infections

IndicationsUsed prophylactically after procedures with high risk of wound complications (eg, ventral hernia repair, select cesarean deliveries, vascular groin incisions)

Evidence summaryRCTs and observational studies show mixed quality evidence with potential SSI reduction in some high‑risk groups; cost-benefit depends on baseline SSI risk and device price

Fasciotomy definition

DefinitionFasciotomy is surgical decompression of a muscle compartment to treat compartment syndrome; definitive management requires prompt fasciotomy and subsequent wound closure strategies

NPWT roleNPWT (vacuum-assisted closure) is associated with higher primary closure rates and may be used to manage fasciotomy wounds prior to definitive closure

Clinical considerationDiagnosis uses compartment pressures (eg, absolute pressure >30 mmHg or differential <30 mmHg); NPWT applied after fasciotomy once wounds are stable

Incisional NPWT (iNPWT) definition

DefinitionIncisional NPWT (iNPWT) is application of negative pressure therapy to a closed surgical incision intended to reduce wound complications such as SSI and dehiscence

Overlap with pNPWT/ciNPWTiNPWT is used interchangeably with closed‑incision NPWT (ciNPWT) and pNPWT when applied prophylactically to closed incisions

Use casesApplied after cesarean, arthroplasty, vascular and abdominal surgeries in selected high‑risk patients

iNPWT / CiNPWT definitions and overlap

Overlap/definitionsiNPWT and ciNPWT both denote NPWT applied to closed incisions; terms (iNPWT, pNPWT, ciNPWT) are often used variably in literature but share the same core approach of closed‑incision negative pressure

Clinical nuance'Prophylactic' emphasizes preventive use; 'closed incision' emphasizes the application site—terminology should be clarified in documentation and authorization requests

Evidence noteSystematic reviews show benefit in select high‑risk groups (eg, obese cesarean patients, revision arthroplasty) but mixed results overall

NPWT pressure settings (typical values)

Typical settingsCommon continuous pressures reported include -125 mmHg and -75 mmHg

Trial comparisonsSome RCTs compared -125 mmHg versus -75 mmHg and versus standard care depending on indication

Clinical selectionPressure selection depends on wound type, tissue tolerance, and therapeutic goals (exudate management vs graft fixation)

s-NPWT (single-use) definition

Definitions‑NPWT (single‑use NPWT) is a disposable, portable, canister‑less NPWT system intended for outpatient or prophylactic use

Comparative evidenceRandomized trials show s‑NPWT can achieve non‑inferior or superior wound area/depth reduction versus t‑NPWT in select VLU/DFU trials, with potential cost savings

Appropriate uses‑NPWT may be preferred for ambulatory patients and prophylactic closed‑incision use, depending on wound size and exudate requirements

t-NPWT (traditional) definition

Definitiont‑NPWT (traditional NPWT) denotes reusable, canister‑based systems with pumps, dressing kits and collection canisters, typically used for larger or complex wounds and inpatient care

ComponentsIncludes an electrical pump capable of continuous/intermittent modes, sensors/alarms, dressing sets and exudate canisters

Use casePreferred for high‑exudate wounds, long‑term inpatient therapy, or where higher negative pressures are needed

ciNPWT definition

DefinitionciNPWT: closed‑incision NPWT applied over surgical incisions to reduce drainage and wound complications

Evidence summarySystematic reviews/meta‑analyses report reduced SSI in revision arthroplasty and spinal fusion but increased non‑infectious complications (eg, blistering) after some primary procedures

Clinical applicationConsider ciNPWT for high‑risk or revision arthroplasty patients rather than routine use for all primary procedures

STSG bolster NPWT definition

DefinitionSTSG bolster NPWT: NPWT used as a bolster to secure split‑thickness skin grafts, promoting graft adherence and reducing hematoma/seroma formation

EvidenceMeta‑analyses and cohort/RCT data report higher graft take and reduced re‑operation with NPWT versus conventional therapy

Practical noteLow‑cost alternatives (eg, gauze sealed with wall suction) produced comparable graft take in some RCTs; device selection may consider cost and setting

VeraFlo / NPWT with instillation definition

DefinitionVeraFlo / NPWT with instillation: NPWT combined with periodic instillation of a solution (eg, normal saline or antiseptic) with dwell cycles applied to the wound bed

System distinctionNPWTi‑d systems provide automated volumetric control and timed dwell cycles compared with continuous instillation approaches

Evidence notePreclinical and clinical studies suggest faster granulation and fewer OR visits for infected wounds, but optimal solution choice is unresolved

ciNPWT definition (duplicate reference)

Definition (duplicate)Closed‑incision negative pressure wound therapy applied over surgical incisions to potentially reduce surgical site infection and wound complications

Clinical nuanceTerm ciNPWT used interchangeably with iNPWT/pNPWT in literature; document intended use clearly in requests

Evidence reminderBenefit most consistent in high‑risk or revision arthroplasty and some vascular/hernia repairs; not uniformly beneficial for all primary incisions

NPWT pump definition and required pressure range

DefinitionNPWT pump: a stationary or portable electrical pump that provides controlled subatmospheric pressure, with capability for continuous or intermittent modes and built‑in sensors/alarms

Required pressure rangePump must be controllable in a range of 40–80 mm Hg subatmospheric pressure for purposes of this policy specification

System requirementsPump must interface with dressing kits and canisters and monitor exudate volume; alarms/sensors required

NPWT dressing kit definition

DefinitionNPWT dressing kit: a dressing set used for each complete dressing change containing porous dressings, drainage tubing, and occlusive dressing components

AllowanceOne dressing kit is used per single, complete dressing change

Monthly limit noteUp to 15 dressing kits per wound per month considered medically necessary unless larger wounds require more

NPWT collection canister definition

DefinitionNPWT collection canister: a canister set used with NPWT pumps to collect wound exudate; available in various sizes for stationary or portable pumps

AllowanceStandard allowance: up to 10 canister sets per month unless >90 ml/day documented

High‑volume guidanceFor high‑volume exudative wounds, use stationary pump with largest capacity canister

Regulatory classification note from FDA regarding non-powered suction devices

Regulatory noteFDA classified non‑powered suction apparatus devices intended for NPWT in a final rule (2010) addressing medical device classification

ImplicationNon‑powered devices (eg, SNaP) are class II devices with 510(k) clearance but lack extensive comparative outcome data

Policy stancePolicy lists non‑powered mechanical NPWT devices and some single‑use systems as experimental/investigational due to limited evidence

Policy Revision History

1999-08-16policy_effective

Policy effective date (original effective date).

2023-12-13last_review

Policy was last reviewed on 12/13/2023.

2024-03-28next_review_scheduledLatest

Next scheduled policy review date set for 03/28/2024.